This Article Abstract Full Text Full Text (PDF) Erratum (v41,p1853) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Morrow, D. A. Articles by Braunwald, E. Search for Related Content PubMed PubMed Citation Articles by Morrow, D. A. Articles by Braunwald, E.

Evaluation of B-type natriuretic peptide for risk assessment in unstable Angina/Non–ST-elevation myocardial infarction

B-type natriuretic peptide and prognosis in TACTICS-TIMI 18

David A. Morrow, MD, MPH^*,*, James A. de Lemos, MD, Marc S. Sabatine, MD, MPH^*, Sabina A. Murphy, MPH, Laura A. Demopoulos, MD, Peter M. DiBattiste, MD, Carolyn H. McCabe, BS^*, C. Michael Gibson, MD, MS, FACC, Christopher P. Cannon, MD, FACC^* and Eugene Braunwald, MD, FACC^*

^* Cardiovascular Division, Department of Medicine, Brigham & Women’s Hospital, Boston, Massachusetts, USA
Donald W. Reynolds Cardiovascular Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Harvard Clinical Research Institute, Boston, Massachusetts, USA
Merck & Co, West Point, Pennsylvania, USA

View larger version (19K): [in a new window]   Figure 1 Kaplan-Meier estimates of the probability of death (A) and death or congestive heart failure (CHF) (B) through six months among patients with baseline concentration of B-type natriuretic peptide (BNP) >80 pg/ml and 80 pg/ml. The p values are based on the log-rank test.

View larger version (20K): [in a new window]   Figure 2 Mortality risk stratified by B-type natriuretic peptide (BNP) levels over range of 40 to 160 pg/ml. The odds ratio (ORs) and chi-squared (2) statistics in the table below the chart are based on BNP results dichotomized at the lower bound of the range.

View larger version (18K): [in a new window]   Figure 3 Risk of death or myocardial infarction (MI) at 30 days stratified by B-type natriuretic peptide (BNP) and cardiac troponin I (cTnI). NEG = negative; POS = positive.

View larger version (18K): [in a new window]   Figure 4 Risk of congestive heart failure (CHF) at 30 days stratified by B-type natriuretic peptide (BNP) and cardiac troponin I (cTnI). NEG = negative; POS = positive.

View larger version (23K): [in a new window]   Figure 5 Effect of the invasive (INV) versus conservative (CON) management strategy stratified by baseline levels of B-type natriuretic peptide (BNP) and cardiac troponin I (cTnI). ACS = acute coronary syndrome; NEG = negative; POS = positive.